Cipla Results

The company bets on Eli Lilly tie-up for GLP-1 drug, biosimilars expansion; reaffirms $1 billion US revenue goal

Umang Vohra was responsible for leading Cipla through a phase of strategic transformation, strengthening its global leadership in respiratory therapies, and digital and manufacturing capabilities

Pharma major Cipla Ltd on Thursday reported a 3.7 per cent rise in consolidated net profit at Rs 1,353.37 crore for the second quarter ended September 30, 2025. The company had posted a consolidated net profit of Rs 1,305.01 crore in the second quarter of the last fiscal year, Cipla Ltd said in a regulatory filing. Consolidated total revenue from operations in the second quarter stood at Rs 7,589.44 crore, as against Rs 7,051.02 crore in the year-ago period, it added. Total expenses in the quarter under review were higher at Rs 6,004.86 crore, as compared to Rs 5,452.57 crore in the corresponding period last fiscal, the company said. In the second quarter, the pharmaceuticals segment clocked revenue of Rs 7,291.43 crore, as against Rs 6,775.56 crore in the same period a year ago. New ventures registered revenue of Rs 350.68 crore, as against Rs 319.6 crore, the filing said.

Cipla is expected to report a profit after tax (PAT) of ₹1,361.6 crore for the September 2025 quarter, against ₹1,302.5 crore in Q2FY25

Sensex Today | Stock market close highlights on Friday, July 25, 2025: In the broader markets, the Nifty MidCap index fell 1.61 per cent, and the Nifty SmallCap index edged 2.1 per cent lower

The company said that its revenue fro the One-India business (operations within India) grew 6 per cent year-on-year, crossing ₹3,000 crore for the first time in any opening quarter of a financial year

Q1 FY26 company results, July 25: Bajaj Finserv, Shriram Finance, Reliance Infrastructure, Orient Cement, and ACME Solar will also release their April-June quarter earnings reports today

Cipla share price today: Cipla shares today declined 2.9 per cent intraday to hit a low of ₹1,474.1 per share

Profit exceeded Bloomberg estimates by 19.4 per cent, whereas the revenue fell along the expected lens growing 0.28 per cent

Cipla Q4 FY25 result: Board of directors recommend a final dividend of ₹14 per equity share for FY25 and a special dividend of ₹3 per share

Q4 FY25 company results: GAIL (India), Aditya Birla Capital, and GlaxoSmithKline Pharmaceuticals will also be releasing their Jan-March quarter results on May 13

In the previous trading session, Sensex jumped 2,975.43 points, or 3.7 per cent, to close at 82,429.90 levels. The Nifty50 closed at 24,924.7, up by 916.7 points, or 3.8 per cent.

Cipla said USFDA has approved the ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial ('Protein-bound Paclitaxel') on Apr 10

Cipla's stock was up 3 per cent during the day's trade on the BSE in the afternoon

The company's consolidated net profit increased nearly 49 per cent to Rs 1,571 crore ($181.6 million) in the October-December quarter,

At 6:31 AM, GIFT Nifty futures pointed to a positive start, trading 76 points higher at 22,922

The uptick in Cipla share price came after the United States Food and Drug Administration (USFDA) on Wednesday classified Goa facility as Voluntary Action Indicated (VAI)

Drug major Cipla on Tuesday reported a 17 per cent increase in consolidated net profit to Rs 1,303 crore for the second quarter ended September 2024, driven by robust sales across markets. The company had reported a net profit of Rs 1,115 crore in the July-September quarter of the last fiscal. Its total income from operations rose to Rs 7,051 crore in the second quarter compared to Rs 6,490 crore in the year-ago period, Cipla said in a regulatory filing. "In Q2 FY25, we recorded a revenue growth of 9 per cent over the last year with a highest-ever EBITDA margin of 26.7 per cent driven by mix and other operational efficiencies," Cipla MD and Global CEO Umang Vohra said. The company's 'One-India' business was impacted during the quarter due to a changed seasonal pattern. However key chronic therapies in the branded prescription business continued to grow faster than the market, he added. The company's consumer health business grew at a strong 21 per cent year-on-year, Vohra said. "

Shares of Cipla dropped 3.55 per cent at Rs 1,450 per share on the BSE in Tuesday's intraday trade

Analysts expect Cipla to register a low single digit rise in the topline and bottomline, with margins being impacted by modest sales in the US and domestic formulations